^
BIOMARKER:

FGFR3-TACC3 fusion

i
Other names: FGFR3, ACH, CD333, CEK2, JTK4, Fibroblast growth factor receptor 3, TACC3, Transforming acidic coiled-coil containing protein 3, ERIC-1
Entrez ID:
FGFR3-TACC3 fusion
Gastric Cancer
TAS 120
Sensitive: C3 – Early Trials
Cancer Discov - 4 weeks
FGFR3-TACC3 fusion
GBM
anlotinib
Sensitive: C3 – Early Trials
FGFR3-TACC3 fusion
Urothelial Cancer
infigratinib
Sensitive: C3 – Early Trials
FGFR3-TACC3 fusion
Urothelial Cancer
Debio 1347
Sensitive: C3 – Early Trials
FGFR3-TACC3 fusion
GBM
erdafitinib
Sensitive: C3 – Early Trials
FGFR3-TACC3 fusion
NSCLC
infigratinib
Sensitive: C3 – Early Trials
FGFR3-TACC3 fusion
NSCLC
ponatinib
Sensitive: C3 – Early Trials
FGFR3-TACC3 fusion
Glioma
anlotinib
Sensitive: C4 – Case Studies
FGFR3-TACC3 fusion
Endometrial Cancer
erdafitinib
Sensitive: C4 – Case Studies
FGFR3-TACC3 fusion
Bladder Cancer
erdafitinib
Sensitive: C4 – Case Studies
FGFR3-TACC3 fusion
Urothelial Cancer
atezolizumab
Sensitive: C4 – Case Studies
FGFR3-TACC3 fusion
Urothelial Cancer
erdafitinib
Sensitive: D – Preclinical
FGFR3-TACC3 fusion
Bladder Cancer
MPT0L145
Sensitive: D – Preclinical
FGFR3-TACC3 fusion
Cholangiocarcinoma
infigratinib
Sensitive: D – Preclinical
FGFR3-TACC3 fusion
Urothelial Cancer
dasatinib + infigratinib
Sensitive: D – Preclinical